BR101801
Phase 2Small molecule
Boryung Pharmaceutical Co., LtdBR101801 is one of 5 small molecule programs targeting PTCL. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in PTCL
#DrugCompanyPhaseTrials
1Opzelura
DDizal Pharmaceuticals
Phase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Mitoxantrone Hydrochloride Liposome
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 2
Zeprumetostat
SSun Yat-sen University
Phase 2
BR101801
Boryung Pharmaceutical Co., LtdPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BR101801. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details